Although aberrant expression of MYC is observed in many solid tumors as well as leukemia, MYCN is more commonly associated with neuroblastoma and other neuroendocrine tumors and MYCL is predominantly deregulated in small‐cell lung cancer. Here, MYCN is linked to neuroblastoma.